For the WikiDoc page for this topic, click here
Viral hemorrhagic fever |
Viral hemorrhagic fever On the Web |
---|
Risk calculators and risk factors for Viral hemorrhagic fever |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. The term "viral hemorrhagic fever" commonly describes a severe multi-organ syndrome. In this condition the vascular system is usually affected, diminishing the body's ability to regulate itself. The symptoms may include bleeding, however, this is seldom life-threatening. The severity of the disease will depend on the underlying virus causing it, and can range from mild to life-threatening. Geographically, these viruses are distributed over the globe. However, since each virus has its own host, some diseases are more commonly seen in certain areas than others.
Signs and symptoms may vary according to the disease, but in general, patients with VHF present with:
Signs seen with specific viruses may include:
Because the incubation period may be as long as 21 days, patients may not develop illness until returning from travel; therefore, a thorough travel and exposure history are critical.
Viral hemorrhagic fevers (VHFs) are caused by several families of enveloped RNA viruses, including:
These families of viruses share some common features, including:
The virus responsible for the VHF may be transmitted through:
Some VHFs are spread on person to person basis, through direct contact with symptomatic patients, body fluids, cadavers or through inadequate infection control measures (filoviruses, arenaviruses, CCHF virus). Zoonotic spread includes the following:
If you think you are developing symptoms of this disease contact your doctor. Common symptoms of Viral hemorrhagic fever include:
US-based clinicians should notify CDC’s Viral Special Pathogens Branch immediately of any suspected cases of VHF occurring in patients residing in or requiring evacuation to the United States: 404-639-1115 or the CDC Emergency Operations Center at 770-488-7100 after hours. CDC also provides consultation for international clinicians and health ministries. Whole blood or serum may be tested for virologic (RT-PCR, antigen detection, virus isolation) and immunologic (IgM, IgG) evidence of infection. Tissue may be tested with the following tests:
Postmortem skin biopsies fixed in formalin and blood collected within a few hours after death by cardiac puncture can be used for diagnosis. Samples should be sent for testing to a reference laboratory with biosafety level 3 and 4 capability.
In most cases there is no specific treatment, with supportive care being the only remaining alternative. Ribavirin, an anti-viral drug, has been effective for treating Lassa fever, New World arenaviruses, and likely CCHF. However, it is not approved by the Food and Drug Administration (FDA) for these indications. Convalescent-phase plasma is effective in treating Argentine hemorrhagic fever.
Directions to Hospitals Treating Viral hemorrhagic fever
Hemorrhagic fever varies in severity. Severe infections with internal bleeding and fever (hemorrhagic fever) are deadly in up to half of cases.
The risk of acquiring VHF is very low for international travelers. Travelers at increased risk for exposure include:
Prevention should focus on avoiding contact with host or vector species:
Investigational vaccines exist for Argentine hemorrhagic fever and RVF however, neither is approved by FDA or commonly available in the United States.
The CDC in conjunction with the WHO, has developed practical, hospital-based guidelines, titled Infection Control for Viral Haemorrhagic Fevers In the African Health Care Setting.
http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/viral-hemorrhagic-fevers.htm
http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/vhf.htm
Template:WSTemplate:WH